WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares WAVE Life Sciences and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| WAVE Life Sciences | -296.86% | -44.66% | -36.80% |
| Ligand Pharmaceuticals | 20.27% | 5.22% | 2.74% |
Risk & Volatility
Valuation & Earnings
This table compares WAVE Life Sciences and Ligand Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| WAVE Life Sciences | $42.73 million | 12.55 | -$204.38 million | ($1.07) | -2.54 |
| Ligand Pharmaceuticals | $268.09 million | 21.41 | $124.45 million | $2.24 | 128.10 |
Ligand Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for WAVE Life Sciences and Ligand Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| WAVE Life Sciences | 1 | 2 | 15 | 2 | 2.90 |
| Ligand Pharmaceuticals | 0 | 1 | 8 | 0 | 2.89 |
WAVE Life Sciences currently has a consensus target price of $20.44, suggesting a potential upside of 651.63%. Ligand Pharmaceuticals has a consensus target price of $355.38, suggesting a potential upside of 23.85%. Given WAVE Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Ligand Pharmaceuticals.
Summary
Ligand Pharmaceuticals beats WAVE Life Sciences on 9 of the 14 factors compared between the two stocks.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
